A Phase 2 Randomized Double-blind Study of Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy vs Placebo with Pembrolizumab and Chemotherapy in Front-line Metastatic KEAP1/NRF2- mutated Nonsquamous Non-Small Cell Lung (NSCLC)
Brief description of study
The purpose of the study is to determine the safety and efficacy of telaglenastat in combination with pembrolizumab plus chemotherapy compared with placebo in combination with pembrolizumab plus chemotherapy as first-line treatment of patients with metastatic KEAP1- or NRF2-mutated nonsquamous Stage IV Non-Small Cell Lung Cancer (NSCLC). We want to know if one treatment is better than another.
Clinical Study Identifier: s19-01766
ClinicalTrials.gov Identifier: NCT04265534
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
